We'll walk you through the implementation of a cutting-edge design workflow. We'll address common challenges in drug discovery, including the protracted time-to-market and inefficiencies of many drugs failing to meet stringent safety and efficacy requirements. We'll share a specific use-case of a cancer-related molecular target, FADS1. We'll explain how the workflow brings together a spectrum of in-silico drug discovery methods: protein structure prediction, binding pocket identification, molecule generation, virtual screening, and ML-powered molecular docking. We'll demonstrate how by employing GPUs and integrating NVIDIA's BioNeMo we have improved the workflow by adding generative models that halve costs, increase calculation potential, and have delivered promising candidates. We'll share learnings and deep dive in to the technical implementations that have enabled this work.